Total ginsenosides synergize with ulinastatin against septic acute lung injury and acute respir atory distress syndrome

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 6, 2015, Pages 7385-7390

  Sun, Rongju ^a   Li, Yana ^b   Chen, Wei ^a   Zhang, Fei ^a   Li, Tanshi ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Department of Surgery   (China)

Author keywords

ALI; ARDS; Ginsenoside; Sepsis; Systemic inflammatory response syndrome; Ulinastatin

Indexed keywords

GINSENOSIDE; GLYCOPROTEIN; TRYPSIN INHIBITOR; ULINASTATIN;

ACUTE LUNG INJURY; ADOLESCENT; ADULT; AGED; COMPLICATION; CONTROLLED STUDY; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; HEMODYNAMICS; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; YOUNG ADULT;

ACUTE LUNG INJURY; ADOLESCENT; ADULT; AGED; DRUG SYNERGISM; FEMALE; GINSENOSIDES; GLYCOPROTEINS; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; TRYPSIN INHIBITORS; YOUNG ADULT;

EID: 84938630484     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Dellinqer RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL and Vincent JL. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008; 34: 17-60.
2. Bakowitz M, Bruns B and McCunn M. Acute lung injury and the acute respiratory distress syndrome in the injured patient. Scand J Trauma Resusc Emerg Med 2012; 20: 54-64.
3. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L and Slutsky AS. Acute respiratory distress syndrome: the Berlin definition. ARDS definition task force. JAMA 2012; 307: 2526-2533.
4. Ito K, Mizutani A, Kira S, Mori M, Iwasaka H and Noguchi T. Effect of ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of acticated leakocytes. Injury 2005; 36: 387-394.
5. Cao ZL, Okazaki Y, Naito K, Ueno T, Natsuaki M and Itoh T. Ulinastatin attenuates reperfusion injury in isolated blood-perfused rabbit heart. Ann Thorac Surg 2000; 69: 1121-1126.
6. Bae HB, Jeong CW, Li M, Kim HS and Kwak SH. Effects of urinary trypsin inhibition on lipopolysaccharide-induced acute lung injury in rabbits. Inflammation 2012; 35: 176-182.
7. Wang N, Liu X, Zheng X, Cao H, Wei G, Zhu Y, Fan S, Zhou H and Zheng J. Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol 2013; 17: 799-807.
8. Inoue K and Takano H. Urinary trypsin inhibitor as a therapeutic option for endoxin-related inflammatory disorders. Expert Opin Investig Drug 2010; 19: 513-520.
9. Inoue K, Takano H, Shimada A, Yanagisawa R, Sakurai M, Yoshino S, Sato H and Yoshikawa T. Urinary trypsin inhibitor protects against systemic inflammatory induced by lipopolysaccharide. Mol Pharmacol 2005; 67: 673-680.
10. Gao C, Li R and Wang S. Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator. J Trauma Acute Care Surg 2012; 72: 169-176.
11. Meng XX, Wang RL, Gao S, Xie H, Tan JT and Qian YB. Effect of ulinastatin on paraquat-induced-oxidiative stress in human type II alveolar epithelial cells. World J Emerg Med 2013; 4: 133-137.
12. Yi XQ, Li T, Wang JR, Wong VK, Luo P, Wong IY, Jiang ZH, Liu L and Zhou H. Total ginsenosides increase coronary perfusion flow in isolated rat hearts through activation of PI3K/Akt-eNOS signaling. Phytomedicine 2010; 17: 1006-1015.
13. Kim TW, Joh EH, Kim B and Kim DH. Ginsenosides Rg5 ameliorates lung inflammation in mice by inhibiting the binding of LPS to toll-like receptor-4 on macrophages. Int Immunopharmacol 2012; 12: 110-116.
14. Shin YM, Jung HJ, Choi WY and Lim CJ. Antioxidative, anti-inflammatory, and matrix metalloproteinase inhibitory activities of 20(S)-ginsenoside Rg3 in cultured mammalian cell lines. Mol Biol Rep 2013; 40: 269-279.
15. Lee SM. Anti-inflammatory effects of ginsenosides Rg5, Rz1, and Rk1: Inhibition of TNF-a induced NF-kB, COX-2, and iNOS transcriptional expression. Phytother Res 2014; 28: 1893-1896.
16. Wong AS, Che CM and Leung KW. Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview. Nat Prod Rep 2015; 32: 256-72.
17. Wu LL, Jia BH, Sun J, Chen JX, Liu ZY and Liu Y. Protective effects of ginsenoside Rb1 on septic rats and its mechanism. Biomed Environ Sci 2014; 27: 300-303.
18. Zhang ZG, Niu XY, He XJ and Shu J. Ginsenoside Rg1 reduces toxicity of fine particulate matter on human alveolar epithelial cells: a preliminary observation. Mol Med Rep 2014; 9: 989-992.
19. Costa EL and Amato MB. The new definition for acute lung injury and acute respiratory distress syndrome: is there room for improvement? Curr Opin Crit Care 2013; 19: 16-23.
20. Dushianthan A, Grocott MP, Postle AD and Cusack R. Acute respiratory distress syndrome and acute lung injury. Postgrad Med J 2011; 87: 612-622.